ATOSSA THERAPEUTICS, INC.
Data quality: 83%
ATOS
Nasdaq
Manufacturing
Chemicals
$4.91
▲
$0.09
(1.87%)
Mkt Cap: 42.28 M
Price
$4.91
Mkt Cap
42.28 M
Day Range
$4.73 — $5.05
52-Week Range
$3.76 — $19.35
Volume
36,445
Open $4.84
50D / 200D Avg
$5.39
8.97% below
50D / 200D Avg
$10.51
53.28% below
Quick Summary
Key Takeaways
Negative free cash flow of -29.79 M
Growth
Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A
Quality
Return on Equity
-64.70%
Below sector avg (-53.47%)
ROIC-54.60%
Net MarginN/A
Op. MarginN/A
Safety
Debt / Equity
N/A
Current Ratio6.77
Interest CoverageN/A
Valuation
PE (TTM)
-1.22
Above sector avg (-1.47)
P/B Ratio0.85
EV/EBITDAN/A
Dividend YieldN/A
Price History
Financial Trends
Peer Comparison
vs Manufacturing sector median (1364 peers)
Peer Comparison
vs Manufacturing sector median (1364 peers)| Metric | Stock | Sector Median |
|---|---|---|
| P/E | -1.2 | -1.5 |
| P/B | 0.9 | 1.6 |
| ROE % | -64.7 | -53.5 |
| Net Margin % | — | -41.5 |
| Rev Growth 5Y % | — | 1.8 |
| D/E | — | 0.3 |
All Fundamental Metrics
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | N/A | Revenue Growth (3Y) | N/A |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | N/A | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | N/A | Net Income (TTM) | -34.77 M |
| ROE | -64.70% | ROA | -56.75% |
| Gross Margin | N/A | Operating Margin | N/A |
| Net Margin | N/A | Free Cash Flow (TTM) | -29.79 M |
| ROIC | -54.60% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | N/A | Current Ratio | 6.77 |
| Interest Coverage | N/A | Asset Turnover | N/A |
| Working Capital | 47.45 M | Tangible Book Value | 49.79 M |
| Dividends | |||
| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | -1.22 | Forward P/E | N/A |
| P/B Ratio | 0.85 | P/S Ratio | N/A |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | N/A | Fwd Earnings Yield | N/A |
| FCF Yield | -70.44% | ||
| Market Cap | 42.28 M | Enterprise Value | -9.56 M |
| Per Share | |||
| EPS (Diluted TTM) | -4.04 | Revenue / Share | N/A |
| FCF / Share | -3.46 | OCF / Share | -3.46 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
| Efficiency | |||
| CapEx / Revenue | N/A | FCF Conversion | 85.66% |
| SBC-Adj. FCF | -32.68 M | Growth Momentum | N/A |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Net Income | -34.77 M | -25.50 M | -30.09 M | -26.96 M | -20.61 M |
| EPS (Diluted) | -4.04 | -0.20 | -0.24 | — | — |
| Gross Profit | — | — | — | — | — |
| Operating Income | -37.14 M | -27.62 M | -31.38 M | -27.69 M | -20.52 M |
| EBITDA | — | — | — | — | — |
| R&D Expenses | 21.19 M | 14.12 M | 17.33 M | 15.08 M | 9.21 M |
| SG&A Expenses | — | — | — | — | — |
| D&A | — | — | — | 8,000.0 | 23,000.0 |
| Interest Expense | — | — | — | — | — |
| Income Tax | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 47.61 M | 76.44 M | 96.25 M | 123.53 M | 141.26 M |
| Total Liabilities | 8.26 M | 4.97 M | 5.24 M | 5.57 M | 3.13 M |
| Shareholders' Equity | 39.35 M | 71.48 M | 91.02 M | 117.96 M | 138.14 M |
| Total Debt | — | — | — | — | — |
| Cash & Equivalents | 41.30 M | 71.08 M | 88.46 M | 110.89 M | 136.38 M |
| Current Assets | 45.62 M | 74.46 M | 92.22 M | 118.20 M | 141.24 M |
| Current Liabilities | 8.26 M | 4.97 M | 5.24 M | 5.57 M | 3.13 M |
{"event":"ticker_viewed","properties":{"ticker":"ATOS","listing_kind":"stock","pathname":"/stocks/atos","exchange":"Nasdaq","country":"US"}}